ReviewHuman vaccines & immunotherapeutics2025
Research hotspots and trends in tumor vaccine adjuvants: A bibliometric analysis from 2010 to 2024.
Review in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor vaccine adjuvants play a critical role in enhancing anti-tumor immune responses, and it is essential to summarize their research hotspots and future trends. This study retrieved and evaluated 6,177 publications on tumor vaccine adjuvants from the Web of Science Core Collection between 2010 and 2024. Most publications originated from the United States and China, with the Chinese Academy of Sciences being the most productive institution. George E. Peoples published 29 articles, and the journal Vaccine had the highest publication frequency. Keyword co-occurrence analysis reflects a research paradigm shift from theoretical exploration to delivery system optimization and clinical translation: earlier studies focused on fundamental immune mechanisms (e.g. "dendritic cell," "immune response," "antigen"), while recent research has turned toward translational technologies (e.g. "drug delivery," "nanoparticles"). Future studies may focus on optimizing delivery systems, exploring novel adjuvants, advancing clinical translation, and further elucidating the mechanisms by which adjuvants enhance immune responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.